The investigational once-weekly drug lowered A1C and body weight in adults with type 2 diabetes, with Novo Nordisk planning Phase III testing in the second half of 2026.  Novo Nordisk reported Phase II data showing that its investigational once-weekly injectable drug zenagamtide reduced both blood sugar and body weight in adults with type 2 diabetes. […]